Brokers Set Expectations for TARS Q3 Earnings

Key Points

• William Blair forecasts Tarsus Pharmaceuticals to post a Q3 2025 EPS of ($0.38), with a full-year estimate of ($3.17) per share.
• Tarsus Pharmaceuticals reported Q2 earnings of ($0.48) per share, missing the consensus estimate by ($0.15), despite exceeding revenue expectations with $102.66 million.
• Institutional investors own 90.01% of Tarsus Pharmaceuticals, indicating strong support from hedge funds and other large investors.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at William Blair issued their Q3 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a note issued to investors on Wednesday, August 6th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings of ($0.38) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals' Q4 2025 earnings at $0.02 EPS, FY2025 earnings at ($1.46) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at $0.23 EPS, Q3 2026 earnings at $0.40 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $1.39 EPS.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 target price on the stock. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target on the stock in a report on Tuesday, May 27th. Finally, Guggenheim boosted their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $66.67.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS traded down $0.28 during midday trading on Monday, hitting $52.44. The company's stock had a trading volume of 106,919 shares, compared to its average volume of 659,439. Tarsus Pharmaceuticals has a 1-year low of $24.95 and a 1-year high of $57.28. The firm's fifty day moving average price is $42.02 and its 200-day moving average price is $45.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. The firm has a market cap of $2.21 billion, a P/E ratio of -22.58 and a beta of 0.79.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). The company had revenue of $102.66 million during the quarter, compared to the consensus estimate of $95.81 million. Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in TARS. Geode Capital Management LLC grew its holdings in Tarsus Pharmaceuticals by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 838,804 shares of the company's stock worth $46,456,000 after acquiring an additional 3,014 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Tarsus Pharmaceuticals by 44.1% in the 4th quarter. Wells Fargo & Company MN now owns 57,004 shares of the company's stock valued at $3,156,000 after purchasing an additional 17,451 shares during the last quarter. Federated Hermes Inc. bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $4,303,000. Invesco Ltd. boosted its stake in shares of Tarsus Pharmaceuticals by 36.7% in the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock valued at $51,611,000 after purchasing an additional 250,018 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $1,107,000. Institutional investors own 90.01% of the company's stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $50.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer owned 818,106 shares of the company's stock, valued at $40,905,300. This represents a 0.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.97% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.